- Home
- IIF vs MREO Comparison
IIF vs MREO Comparison
Compare IIF & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IIF | MREO |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.2M | 286.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IIF | MREO |
|---|---|---|
| Price | $26.61 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 45.4K | ★ 1.9M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 13.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $131.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.95 | $1.47 |
| 52 Week High | $24.41 | $3.94 |
Technical Indicators
Market Signals| Indicator | IIF | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 41.38 | 58.62 |
| Support Level | $26.52 | $1.75 |
| Resistance Level | $27.51 | $1.89 |
| Average True Range (ATR) | 0.30 | 0.12 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 4.04 | 53.41 |
Price Performance
Historical ComparisonAbout IIF Morgan Stanley India Investment Fund Inc.
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).